Research associate

George Ortega Promoted to Portfolio Manager on Several Alger Growth Equity and Long/Short Strategies

Retrieved on: 
Wednesday, January 17, 2024
Senior, Portfolio, Research, Credit Suisse, Intelligence, Research associate, Yale University, Goldman Sachs, Management

NEW YORK, Jan. 17, 2024 /PRNewswire-PRWeb/ -- Fred Alger Management, LLC ("Alger"), a $22 billion growth equity investment manager, is pleased to announce that George Ortega has been promoted to Portfolio Manager and will be responsible for several growth equity and long/short equity strategies.

Key Points: 
  • Alger announced that George Ortega has been added as a Portfolio Manager to the Alger Dynamic Return, Alger Dynamic Opportunities and Alger 35 strategies.
  • NEW YORK, Jan. 17, 2024 /PRNewswire-PRWeb/ -- Fred Alger Management, LLC ("Alger"), a $22 billion growth equity investment manager, is pleased to announce that George Ortega has been promoted to Portfolio Manager and will be responsible for several growth equity and long/short equity strategies.
  • George, who joined Alger in 2013, has been added as a Portfolio Manager to the Alger Dynamic Return, Alger Dynamic Opportunities and Alger 35 strategies.
  • George Ortega is Senior Vice President, Portfolio Manager and Senior Analyst on the Alger 35, Alger Dynamic Opportunities and Alger Dynamic Returns strategies.

7 Days to Go for the 36th Edition of TRUSTECH, the International Event Dedicated to Innovative Payments and Identification

Retrieved on: 
Tuesday, November 22, 2022
Technology, Finance, Apps, Applications, Small Business, Banking, Electronic Commerce, Professional Services, Payments, Digital Cash Management, Digital Assets, Other Technology, Fintech, Data Management, Security, Consumer Electronics, University of Oxford, Research associate, Heart, Professor, Cryptocurrency

During 3 days, actors and professionals of the innovative payments and identification solutions sector will meet to exchange on the themes of innovative payments and identification solutions, real pillars of the digital transition for institutional or commercial organizations.

Key Points: 
  • During 3 days, actors and professionals of the innovative payments and identification solutions sector will meet to exchange on the themes of innovative payments and identification solutions, real pillars of the digital transition for institutional or commercial organizations.
  • TRUSTECH will host nearly 130 French and international exhibitors (83%), and many start-ups.
  • This is an opportunity to present their latest innovations, or to participate in pitch sessions on the Innovation Stage , an area located at the heart of the event.
  • Come to Paris Porte de Versailles on 29 November to discover all the technological innovations around digital identity and payment.

Innopshere Ventures Hires Accomplished COO

Retrieved on: 
Tuesday, August 23, 2022
COO, University, Energy, Research, Technology, Graduate school, Program, BS, Joseph M. Katz Graduate School of Business, Culture, RVC, Fund, Mechanical, Science, SAMPL, Community, Water, MBA, GLOBE, ICEX: US Navy Mission in Arctic, GE, Jones, Clean technology, Climate, Research associate, MS, Business, Chief executive officer, Mechanical engineering, Growth, United States Navy, General partnership, Rensselaer Polytechnic Institute, General Electric, Venture, Private sector, Private investigator, Intelligence

Fort Collins, Colorado, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Innosphere Ventures has announced that Tim Jones has been appointed new COO of the company.

Key Points: 
  • Fort Collins, Colorado, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Innosphere Ventures has announced that Tim Jones has been appointed new COO of the company.
  • The Fund partners with Innosphere Ventures , Colorados leading technology incubator to commercialize the technology in the US.
  • Jones is also a Principal within Innosphere Ventures Fund II where he leads the diligence process.
  • About Innosphere Ventures:Innosphere Ventures accelerates the success of science and technology-based startups through its unique accelerator and commercialization programs, specialized laboratory facilities, and venture capital fund.

Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy Development

Retrieved on: 
Tuesday, August 2, 2022
National, Algorithm, NIH, RNA splicing, Research associate, Genome, Small Business Innovation Research, Neurodegeneration, Research, SBIR, IO, National Institute, Artificial intelligence, National Institute of General Medical Sciences, Risk, National Cancer Institute, Robert H. Lurie Comprehensive Cancer Center, Machine learning, Biotechnology, Disease, Cold, Patient, Breast cancer, NIGMS, Therapy, Feinberg School of Medicine, RNA-Seq, Breast, Lists of diseases, Cold Spring Harbor Laboratory, RNA, NCI, Pharmaceutical industry, Vaccine, Cancer

This grant will provide $2 million over 2 years to commercialize Envisagenics' proprietary drug discovery platform, SpliceIOTM, for the discovery of novel targets for immuno-oncology (IO) therapeutic development.

Key Points: 
  • This grant will provide $2 million over 2 years to commercialize Envisagenics' proprietary drug discovery platform, SpliceIOTM, for the discovery of novel targets for immuno-oncology (IO) therapeutic development.
  • Envisagenics was previously awarded Phase I and Phase II grants from the National Institute of General Medical Sciences (NIGMS, NIH) to develop the SpliceCore software platform.
  • A Phase I SBIR grant was also awarded by the NCI to expand SpliceCore's capabilities for discovery of splicing-derived neoantigens.
  • Envisagenics is a spin-out of Cold Spring Harbor Laboratory and a proud woman- and minority-led recipient of several grants from the National Institute of General Medical Sciences and the National Cancer Institute.

ZyVersa Therapeutics Sponsors American Diabetes Association Thought Leadership Video on Podocyte Lipotoxicity, a Cause of Diabetic Kidney Disease and Its Progression

Retrieved on: 
Friday, June 3, 2022
Science, Kidney, Kidney disease, Statistics, Research associate, Cholesterol, Cell, Research, Focal segmental glomerulosclerosis, Katz, ADA, Inflammation, Transplant, CEO, ASC, American Diabetes Association, Dialysis, Diabetes, Nephrology, Multimedia, University, Alport syndrome, Therapy, Patient, Mouse, Lipid, CNS, Kidney failure, Apoptosis, View, FSGS, Pharmaceutical industry, Medicine

WESTON, Fla., June 3, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases, is pleased to announce sponsorship of an American Diabetes Association Thought Leadership Video on Podocyte Lipotoxicity, a Cause of Diabetic Kidney Disease and Its Progression. The video features researchers at the University of Miami Miller School of Medicine, Dr. Alessia Fornoni (Katz Professor of Medicine, Chief, Katz Family Division of Nephrology & Hypertension & Director of Peggy & Harold Katz Drug Discovery Center) and Dr. Sandra Merscher (Research Associate Professor, Katz Family Division of Nephrology & Hypertension).

Key Points: 
  • Renal Lipotoxicity is a Cause of Kidney Disease and Its Progression Being Addressed by ZyVersa.
  • The video will be shown at The American Diabetes Association's 82nd Scientific Sessions, June 3-7, 2022, as part of their conference television channel (ADA TV).
  • "We observed that kidney cells exposed to sera from patients with diabetic kidney disease accumulate lipids, whereas kidney cells exposed to sera from diabetic patients without kidney disease did not.
  • VAR 200 has potential to treat other kidney diseases, such as Alport Syndrome and Diabetic Kidney Disease.

Melior Announces Substantial Additions to Its Management and Scientific Team

Retrieved on: 
Tuesday, April 12, 2022
Pharmaceutical, Health, Oncology, Foundation for the National Institutes of Health, CEO, Pain, Lists of diseases, LLC, MBA, Doctor of Philosophy, Pfizer, Inflammation, Hospital, GlaxoSmithKline, Research and development, Environment, Research associate, Hospital for Sick Children (Toronto), National Institute, PDX, Toronto, Neurodegeneration, Melior Discovery, Knowledge, Management, Pharmaceutical industry, Oncology, Pharmacology, Melior, Research

Melior Discovery, Inc. (Melior) announced today significant additions to its management organization.

Key Points: 
  • Melior Discovery, Inc. (Melior) announced today significant additions to its management organization.
  • Joining the Melior organization will be Dr. Ken Kilgore (PhD, MBA) as Vice President of Pharmacology.
  • In addition, Melior veteran, Dr. Vivian Cong, will rise to the role of Vice President of Research and Development.
  • Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com .

BPM+ Health Announces Steering Committee

Retrieved on: 
Thursday, January 6, 2022
Knowledge, Mayo Clinic, University of Utah, American College of Surgeons, Health, Chairperson, University, Program, Senior advisor, Physician, Quality, Research associate, MS, Veterans Health Administration, FACS, Health informatics, Department, Veterans' affairs, GLOBE, Object Management Group, Health policy, Interoperability, Hospital, Management, MD, Medicine

BOSTON, MA, Jan. 06, 2022 (GLOBE NEWSWIRE) -- BPM+ Health , a community initiative to improve the quality and consistency of healthcare delivery by capturing and communicating best practices and clinical expertise, announced the formation of its steering committee.

Key Points: 
  • BOSTON, MA, Jan. 06, 2022 (GLOBE NEWSWIRE) -- BPM+ Health , a community initiative to improve the quality and consistency of healthcare delivery by capturing and communicating best practices and clinical expertise, announced the formation of its steering committee.
  • Each BPM+ Health Steering Committee member was nominated and selected by their peers for their knowledge and work in the community.
  • The committee includes academicians, enterprise architects, flight surgeons, informaticians, physicians, public health leaders, researchers, and vendors.
  • "It takes a community of experts to effect and sustain positive change, and at BPM+ Health, we have no shortage of expertise, said Shane McNamee, MD, Executive Director BPM+ Health and Smile CDR.